<DOC>
	<DOCNO>NCT02164266</DOCNO>
	<brief_summary>This study design investigate safety , tolerability , pharmacokinetics , pharmacodynamics RO6799477 follow daily oral administration 2 week healthy volunteer ( Part 1 ) Type 2 diabetes patient ( T2D ) ( Part 2 ) . The anticipated time study treatment two week .</brief_summary>
	<brief_title>A Study Investigate Healthy Volunteers ( Part 1 ) Patients With Type 2 Diabetes Mellitus ( Part 2 ) Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Doses RO6799477</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Part 1 Inclusion criterion : Righthanded male volunteer Aged 1845 year , inclusive Healthy participant , determine screen assessment Principal Investigator 's judgment Healthy status define absence evidence active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead ECG , hematology , blood chemistry , serology urinalysis Body Mass Index ( BMI ) 1830 kg/m2 inclusive , body weight range 50100 kg Part 2 Patients type 2 diabetes accord WHO criterion diagnose least 3 month prior screen Male female patient , 40 65 year age , inclusive Type 2 diabetic patient either drug naive ( diet &amp; exercise alone ) stable dose metformin least 3 month prior screen willing safely stop sulfonylurea medication least 2 week prior first dose administration followup visit BMI 2342 kg/m2 , inclusive Part 1 Exclusion criterion : Any clinically relevant history presence e.g . respiratory , renal , hepatic , gastrointestinal , hematological , lymphatic , neurological , cardiovascular , psychiatric , etc . disease diseases Disorders central nervous system , psychiatric disorder , behavioral disturbance ( e.g . cerebrovascular event , depression , posttraumatic stress disorder [ PTSD ] , anxiety , bipolar disorder , severe migraine , Parkinson 's disease ) Participation investigational drug device study within 3 month prior screen 4 time per year Concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion investigator , pose unacceptable risk subject study Part 2 Type 1 diabetes Acquired secondary form diabetes result pancreatic surgery/injury , cystic fibrosis relate diabetes Evidence history clinically significant diabetic complication clinically severe diabetic peripheral neuropathy , clinically significant nephropathy judge investigator , preproliferative/proliferative diabetic retinopathy judge investigator already diagnose diabetologist general practitioner Disorders central nervous system , psychiatric disorder , behavioral disturbance Clinically significant history presence bronchopulmonary , gastrointestinal , hematological , lymphatic , neurological , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , infectious , connective tissue inflammatory disease , type cancer ( exception treat basal cell carcinoma skin ) clinically significant disease Use antidiabetic drug metformin sulfonylurea within 2 month prior screen Any condition disease detect medical interview / physical examination would render patient unsuitable study , place patient undue risk interfere ability patient complete study opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>